Carmine N. Stengone

CIK: 0001861519

Transaction Breakdown

Open Market Buys (P)1 (5.0%)

High conviction signal

Open Market Sales (S)7 (35.0%)

Position reduction

Option Exercises (M)8 (40.0%)

Derivative conversions

Awards (A)4 (20.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CTNM

Contineum Therapeutics, Inc.

DirectorOfficer

KPRX

KIORA PHARMACEUTICALS INC

Director

Discretionary Trading P&L

Holdings

Transaction History (20 total)

CTNM
Contineum Therapeutics, Inc.
Sep 8, 2026
Sale(S)
Direct
2.5K shares at avg. $16.46$41K
CTNM
Contineum Therapeutics, Inc.
Sep 8, 2026
Exercise(M)
Direct
2.5K shares at avg. $1.01$3K
CTNM
Contineum Therapeutics, Inc.
Aug 3, 2026
Sale(S)
Direct
2.5K shares at avg. $16.01$40K
CTNM
Contineum Therapeutics, Inc.
Aug 3, 2026
Exercise(M)
Direct
2.5K shares at avg. $1.01$3K
CTNM
Contineum Therapeutics, Inc.
Jul 8, 2026
Sale(S)
Direct
2.5K shares at avg. $16.00$40K
CTNM
Contineum Therapeutics, Inc.
Jul 8, 2026
Exercise(M)
Direct
2.5K shares at avg. $1.01$3K
CTNM
Contineum Therapeutics, Inc.
Jun 30, 2026
Exercise(M)
Direct
2.5K shares at avg. $1.26$3K
CTNM
Contineum Therapeutics, Inc.
Jun 30, 2026
Exercise(M)
Direct
7.5K shares at avg. $1.01$8K
CTNM
Contineum Therapeutics, Inc.
Jun 30, 2026
Sale(S)
Direct
10K shares at avg. $16.01$160K
KPRX
KIORA PHARMACEUTICALS INC
Jun 10, 2026
Award(A)
Stock Option (right to buy)
Direct
25K shares-
CTNM
Contineum Therapeutics, Inc.
Feb 25, 2026
Sale(S)
Direct
2.7K shares at avg. $16.02$43K
CTNM
Contineum Therapeutics, Inc.
Feb 25, 2026
Exercise(M)
Direct
2.7K shares at avg. $1.26$3K
CTNM
Contineum Therapeutics, Inc.
Feb 24, 2026
Sale(S)
Direct
4.4K shares at avg. $16.02$70K
CTNM
Contineum Therapeutics, Inc.
Feb 24, 2026
Exercise(M)
Direct
4.4K shares at avg. $1.26$6K
CTNM
Contineum Therapeutics, Inc.
Feb 11, 2026
Exercise(M)
Direct
400 shares at avg. $1.26$504
CTNM
Contineum Therapeutics, Inc.
Feb 11, 2026
Sale(S)
Direct
400 shares at avg. $16.00$6K
CTNM
Contineum Therapeutics, Inc.
Jan 30, 2026
Award(A)
Stock Option (right to buy)
Direct
445K shares-
KPRX
KIORA PHARMACEUTICALS INC
Apr 1, 2025
Award(A)
Stock Option (right to buy)
Direct
20K shares-
CTNM
Contineum Therapeutics, Inc.
Jan 31, 2025
Award(A)
Stock Option (right to buy)
Direct
300K shares-
KPRX
KIORA PHARMACEUTICALS INC
Sep 11, 2024
Purchase(P)
Direct
1.3K shares at avg. $3.68$5K

		Type	Shares	Price		Ownership
Sep 8, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	2,500	$16.46	$41,142	Direct
Sep 8, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	2,500	$1.01	$2,525	Direct
Aug 3, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	2,500	$16.01	$40,029	Direct
Aug 3, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	2,500	$1.01	$2,525	Direct
Jul 8, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	2,500	$16.00	$40,000	Direct
Jul 8, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	2,500	$1.01	$2,525	Direct
Jun 30, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	2,500	$1.26	$3,150	Direct
Jun 30, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	7,500	$1.01	$7,575	Direct
Jun 30, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	10,000	$16.01	$160,080	Direct
Jun 10, 2026	KPRX KIORA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	25,000	-	-	Direct
Feb 25, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	2,700	$16.02	$43,242	Direct
Feb 25, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	2,700	$1.26	$3,402	Direct
Feb 24, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	4,400	$16.02	$70,486	Direct
Feb 24, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	4,400	$1.26	$5,544	Direct
Feb 11, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	400	$1.26	$504	Direct
Feb 11, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	400	$16.00	$6,400	Direct
Jan 30, 2026	CTNM Contineum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	445,000	-	-	Direct
Apr 1, 2025	KPRX KIORA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	20,000	-	-	Direct
Jan 31, 2025	CTNM Contineum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	300,000	-	-	Direct
Sep 11, 2024	KPRX KIORA PHARMACEUTICALS INC	Purchase(P)	1,250	$3.68	$4,600	Direct

1-20 of 20 transactions

About Stengone Carmine N.

Stengone Carmine N. (SEC CIK 0001861519) files insider reports with the SEC as CEO and President of Contineum Therapeutics, Inc. (CTNM) and Director of KIORA PHARMACEUTICALS INC (KPRX).

Signal8 holds 11 ownership filings by Stengone Carmine N., all Form 4s, filed between Sep 12, 2024 and Sep 8, 2026. Those filings report 20 transactions, from Sep 11, 2024 to Sep 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Stengone Carmine N.'s filings is in SAN DIEGO, CA.

Recent filings by Stengone Carmine N.

Sep 8, 2026: Open-market sale of CTNM shares (Form 4, code S).
Sep 8, 2026: Option exercise of CTNM shares (Form 4, code M).
Aug 3, 2026: Open-market sale of CTNM shares (Form 4, code S).
Aug 3, 2026: Option exercise of CTNM shares (Form 4, code M).
Jul 8, 2026: Open-market sale of CTNM shares (Form 4, code S).

Other insiders filing for Contineum Therapeutics, Inc. (CTNM)

Lorrain Daniel S., Chief Scientific Officer
Watkins Tim, CMO & Head of Development
Miralles Gines Diego, Director
Lyons-Williams Lori, Director
Ware Olivia C, Director
Schimmelpennink Evert B., Director

How to read Form 4 transaction codes